Adial Pharmaceuticals Inc... (ADIL)
0.70
0.01 (1.45%)
At close: Apr 03, 2025, 3:56 PM
0.67
-3.88%
After-hours: Apr 03, 2025, 04:48 PM EDT
1.45% (1D)
| Bid | 0.63 |
| Market Cap | 4.59M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| EPS (ttm) | -2.72 |
| PE Ratio (ttm) | -0.26 |
| Forward PE | -0.59 |
| Analyst | Buy |
| Ask | 0.71 |
| Volume | 25,004 |
| Avg. Volume (20D) | 830,408 |
| Open | 0.65 |
| Previous Close | 0.69 |
| Day's Range | 0.64 - 0.70 |
| 52-Week Range | 0.61 - 3.10 |
| Beta | 1.13 |
About ADIL
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a selective serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial...
Industry Biotechnology
Sector Healthcare
IPO Date Jul 27, 2018
Employees 5
Stock Exchange NASDAQ
Ticker Symbol ADIL
Website https://www.adialpharma.com
Analyst Forecast
According to 1 analyst ratings, the average rating for ADIL stock is "Buy." The 12-month stock price forecast is $8, which is an increase of 1044.82% from the latest price.
Stock Forecasts1 month ago
+20.64%
Adial Pharmaceuticals shares are trading higher af...
Unlock content with
Pro Subscription
4 months ago
+15.04%
Adial Pharmaceuticals shares are trading higher after the company announced results from its AD04-103 pharmacokinetics study for AD04, aimed at treating alcohol use disorder.
